Literature DB >> 32557851

Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease.

Chi-Un Choe1, Louisa Niemann1, Catrin Englisch1, Elina Petersen2, Carsten Buhmann1, Monika Pötter-Nerger1, Stefan Blankenberg3,4, Christian Gerloff1, Edzard Schwedhelm4,5, Tanja Zeller3,4.   

Abstract

BACKGROUND: We assessed if cardiac blood markers are associated with motor and cognitive function in patients with Parkinson's disease (PD).
METHODS: High-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were evaluated in 285 PD patients. Furthermore, N-terminal pro-B-type natriuretic peptide levels were analyzed in 570 age, sex and cardiovascular risk factor matched healthy controls. Motor (UPDRS, Hoehn &Yahr) and cognitive function (Montreal Cognitive Assessemtn) were assessed at baseline in all 285 patients and after 1 year in 101 patients.
RESULTS: N-terminal pro-B-type natriuretic peptide were significantly increased in 285 PD patients compared with 570 matched healthy controls. In PD patients, increased high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide levels were associated with worse motor function at baseline and also with motor decline after 1 year. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin I were inversely associated with cognitive function at baseline only in unadjusted models.
CONCLUSIONS: Subclinical cardiac microdamage is associated with motor severity in PD patients.
© 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Montreal cognitive assessment; N-terminal pro-B-type natriuretic peptide; high-sensitivity troponin I

Mesh:

Substances:

Year:  2020        PMID: 32557851     DOI: 10.1002/mds.28129

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  2 in total

1.  Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study.

Authors:  Monika Pötter-Nerger; Janina Dutke; Susanne Lezius; Carsten Buhmann; Robert Schulz; Christian Gerloff; Jens Kuhle; Chi-Un Choe
Journal:  J Neural Transm (Vienna)       Date:  2022-01-24       Impact factor: 3.850

Review 2.  Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.

Authors:  Lars Tönges; Carsten Buhmann; Stephan Klebe; Jochen Klucken; Eun Hae Kwon; Thomas Müller; David J Pedrosa; Nils Schröter; Peter Riederer; Paul Lingor
Journal:  J Neural Transm (Vienna)       Date:  2022-04-15       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.